acalabrutinib for the treatment of richter's transformation and patients with ibrutinib intolerance
Published 7 years ago • 420 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
1:54
nivolumab ibrutinib for patients with richter’s transformation
-
1:50
novel treatment regimens under investigation for richter's transformation
-
1:12
novel treatment strategies for richter’s transformation
-
1:15
the combination of copanlisib and nivolumab in patient's with richter's transformation
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:30
the use of pirtobrutinib in richter's transformation: data from the bruin trial
-
1:47
treatment of richter’s transformation: recent insights
-
1:08
richter’s transformation: the need for more therapeutic agents in this space
-
1:53
animation heal technology
-
5:02
safety and efficacy of amlitelimab in ad: a phase iia rct, s. weidinger et al.
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
1:26
phase i trial of copanlisib nivolumab in patients with richter’s transformation or transformed fl
-
1:15
promising agents emerging for richter’s transformation
-
1:26
treating richter’s transformation with venetoclax, obinutuzumab and atezolizumab
-
2:17
epcore cll-1: epcoritamab in patients with r/r cll & richter's transformation
-
3:16
bruin: pirtobrutinib shows efficacy for richter's transformation
-
1:49
the management of richter's transformation: current approaches and future outlooks
-
3:44
the safety and efficacy of venetoclax-based treatment for patients with richter's syndrome
-
1:42
what's on the horizon for patients with richter's transformation?
-
0:54
a research update in richter's transformation from ash 2023
-
1:56
positive results for acalabrutinib in waldenström's macroglobulinemia